70 results about "Rifampicin" patented technology

The invention relates to the technical field of high-throughput targeted sequencing, in particular to a primer group for detecting important drug-resistant genes and virulence genes of multi-drug-resistant pathogenic bacteria and application of the primer group. Specifically, the kit comprises detection primers for multiple drug-resistant bacteria such as third-generation cephalosporin drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant acinetobacter baumannii, rifampicin drug-resistant mycobacterium tuberculosis and the like. The method has the technical advantages of rapidness, high efficiency, strong targeting property, strong specificity and the like, is suitable for epidemic and difference analysis of various important drug-resistant genes and virulence genes carried by metagenome samples of various environments or disease materials and the like, evaluates the risk of related environments on the basis, and can further guide prevention and clinical treatment medication.

The invention discloses an antibiotic-loaded lubricating antibacterial medical coating as well as a preparation method and application thereof. The preparation method comprises the following steps: coating a polymer substrate embedded with an initiator with a prepolymer solution, and carrying out ultraviolet irradiation reaction to prepare a lubricating hydrogel coating; the preparation method comprises the following steps: sequentially carrying out ultrasonic cleaning in an ethanol solution and an aqueous solution, drying, soaking in an antibiotic solution, regulating and controlling the loading capacity of antibiotics by controlling the pH value of the antibiotic solution, taking out, washing with the aqueous solution, and drying to obtain the lubricating antibacterial coating. According to the method, a hydrogel coating loading platform for loading the antibiotics only through post-adsorption is constructed, the loading capacity of the antibiotics in the coating can be regulated and controlled through the pH value of an antibiotic solution in the post-adsorption process, and the method effectively widens the adjustable range of the loading capacity of the antibiotics such as rifampicin; according to the invention, on-demand regulation and control of antibiotic load and related release curves in the hydrogel coating under different application scenes can be realized, and an effective multifunctional strategy is provided for reducing related infection of interventional medical catheters.

The invention provides a 3D printing bone scaffold based on a TPMS structure, the bone scaffold is prepared by taking Ti-6Al-4V powder as a building raw material through a 3D printing mode, the bone scaffold is a TPMS G unit structure, the aperture range is 420-630 microns, the inner layer porosity is 55%, the peripheral porosity is 90%, the diameter of the scaffold is 15 mm, and the height of the scaffold is 2 mm. Moxifloxacin / rifampicin PLGA microspheres and BMP-2 are loaded in the bone scaffold and are fixed by hydrogel, so that the 3D printing anti-infection bone scaffold based on the TPMS structure is formed. The prepared 3D printing anti-infection bone scaffold highlights excellent performance in all aspects, has good capacity of resisting infection and promoting bone formation, and provides a new material and thought for treatment of infectious bone defects. In addition, the invention further discloses a preparation method and application of the stent.

The invention discloses a detection kit and method for Mycobacterium tuberculosis complex and rifampicin drug-resistant mutation, and belongs to the technical field of biologication.A Taqman probe and a molecular beacon are combined, a fluorescent signal is generated based on a Taq enzyme hydrolysis fluorescent probe, the fluorescent signal is accumulated, and the molecular beacon is used for detecting the drug-resistant mutation of the Mycobacterium tuberculosis complex and the rifampicin drug-resistant mutation of the Mycobacterium tuberculosis complex and the rifampicin drug-resistant mutation. According to two technical principles that a molecular beacon and a fluorescent product are hybridized to generate a fluorescent signal, fluorescent PCR amplification is adopted for detection of one target spot in a monochromatic fluorescent channel, and a melting curve mode of a probe and a target gene is adopted for detection of the other target spot. Therefore, two target spots can be detected and analyzed in a monochromatic fluorescence channel at the same time. Single-tube multiple detection is achieved, and mycobacterium tuberculosis complex group detection and mycobacterium tuberculosis rifampicin drug-resistant mutation site detection can be achieved at the same time.

The invention discloses a compound preparation capsule and a preparation method thereof, wherein the compound preparation capsule is composed of Vonoprasone or a pharmaceutical salt microtablet thereof, an amoxicillin microtablet and a rifampicin or rifampetine microtablet. The Vonoprazan is a novel potassium ion competitive acid blocker, and the compound preparation capsule is used for treating gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and helicobacter pylori infection and helicobacter pylori infection gastritis in the stomach after early gastric cancer endoscopic therapy. According to the compound preparation capsule, the cure rate of helicobacter pylori can be increased, the drug resistance can be reduced, and a better treatment choice is provided for clinical patients.

The invention discloses a primer composition for detecting drug resistance of mycobacterium tuberculosis, a related product and application, and belongs to the field of pathogen detection. The primer composition comprises a primer pair aiming at an rpoB gene, a primer pair aiming at a katG gene, a primer pair aiming at an inhA gene, a primer pair aiming at an ahpC gene, a primer pair aiming at a gyrA gene and a primer pair aiming at a gyrB gene. According to the invention, mutation of mycobacterium tuberculosis complex and rifampicin, isoniazide and quinolone drug resistance related genes rpoB, katG, inhA, ahpC, gyrA and gyrB genes in sputum of a tuberculosis patient can be detected at one time, single-tube multiple high-sensitivity detection is realized, wild genes and mutant genes are accurately distinguished, and serious cross reaction is avoided.

The invention discloses a wrapping material for implantable electronic equipment and a preparation method of the wrapping material. The wrapping material comprises a degradable polymer base material with a porous structure and a drug-loaded slow-release coating uniformly loaded on the degradable polymer base material, holes in the degradable polymer are uniformly distributed in a staggered array mode, the holes are circular, the hole diameter is 0.5-3.0 mm, and the distance between every two adjacent holes is 0.5-3.0 mm. According to the wrapping material disclosed by the invention, the degradable polymer is taken as a base material, and the drug-loading coating containing rifampicin and minocycline hydrochloride is loaded on the surface, so that slow release of antibiotic drugs can be realized, and the wrapping material has excellent antibacterial performance and complete absorbability in a biological environment; and the problems of biocompatibility, infection risk and secondary operation removal faced by the implantable electronic equipment for a long time are solved.

A process for preparing rifampicin substantially free of 1-methyl-4-nitrosopiperazine (MeNP) may include: providing a mixture of crude rifampicin in an organic solvent, wherein the mixture is obtained by dissolving a solid crude rifampicin in the organic solvent; washing the mixture with an aqueous solution, having a pH greater than or equal to 2 and less than or equal to 7, so as to obtain an organic layer and an aqueous layer which are then separated; adding at least one antioxidant to the separated organic layer; distilling the organic solvent under inert atmosphere; crystallizing under the inert atmosphere; and isolating the rifampicin thus obtained under the inert atmosphere.

Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially / fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline.

The application provides a primer probe set and a kit for detecting a rifampicin-resistant gene of Mycobacterium tuberculosis, and belongs to the technical field of molecular biology detection.The primer probe set comprises RAA primers and qPCR primers targeting the rpoB gene, probe primers targeting the wild-type rpoB gene, and probe primers targeting the mutant rpoB gene.The application adopts the detection methods of RT-RAA and qPCR in sequence, and the above specific primer probe set can be combined to simultaneously and rapidly detect the 516, 526, 531 and 533 sites of the rpoB gene of Mycobacterium tuberculosis, has good specificity, and the detection sensitivity can reach 5 copies / ul, is 20 times higher than the sensitivity of qPCR (100 copies / ul), and has a 5% detection capability for heterogenic drug resistance mutation; the detection method can also greatly shorten the detection time.

The promethazine hydrochloride disclosed by the invention has a very good antibacterial effect on the Mycobacterium kansasii, the MIC of the promethazine hydrochloride on the standard strain of the Mycobacterium kansasii is 1.6 mu g / ml, and the MIC of the promethazine hydrochloride on the clinical rifampicin drug-resistant bacteria is 2 mu g / ml. Promethazine hydrochloride has low cytotoxicity and good safety, and can be used as a candidate drug to be applied to the development of anti-Mycobacterium kansasii infection drugs.

The invention belongs to the field of molecular biology detection, particularly relates to detection of tuberculosis drug-resistant genes, and more particularly relates to detection of at least four genes in inhA, KatG, ahpC-2, rpoB-3, rpoB-4 and FabG1 genes. According to the combined detection composition provided by the invention, a multicolor melting curve analysis technology is mainly utilized, different target spots are detected, and drug resistance target spots of pathogens are detected, so that drug resistance detection of isoniazide and rifampicin is realized, and a targeted strategy is provided for subsequent treatment. The composition disclosed by the invention is higher in detection sensitivity (up to 800 bacteria / mL), good in specificity and more accurate in detection, provides more accurate and comprehensive tuberculosis drug-resistant medication guidance for clinicians, and accelerates the implementation of treatment measures on patients.

The present invention discloses a kit and a detection method for detecting gene mutation sites based on fluorescent quantitative PCR using a lock ring probe. The present invention combines the lock ring probe ligation technology in RCA technology with real-time fluorescent quantitative PCR technology, utilizes the lock ring probe ligation characteristics to detect point mutations, and utilizes qPCR technology to achieve signal amplification with high sensitivity and good specificity. It has been used to detect the T478K mutation site of the SARS-cov2-Delta mutant strain, the CD17 mutation site of thalassemia, and the 531 mutation site of the rpoB gene of the rifampicin-resistant strain of Mycobacterium tuberculosis; wherein the minimum detection limit of SARS-cov2 can reach 54.9fM, and the detection limits of thalassemia and tuberculosis resistance are 95.35zM and 55.12aM, respectively. This method can also be widely used in the detection of gene mutation sites related to other diseases.

The invention provides Kineococcus G2 and application of the Kineococcus G2 in preparation of a pigment with antioxidant activity, the Kineococcus new strain G2 is CCTCC No. M20242602, the strain is spherical, the size is 1.0 * 1.5 mu m, the optimal growth temperature is 30-37 DEG C, the pH value is 7.0-9.0, and the salt concentration is 1.0%-2.0%. The strain G2 is not sensitive to bacitracin, ciprofloxacin and norfloxacin, and is sensitive to novobiocin, polymyxin, gentamicin, piperacillin, ofloxacin, erythromycin, streptomycin, kanamycin, rifampicin, ampicillin, vancomycin, carbenicillin, chloramphenicol, tetracycline, penicillin, cefoperazone, oxacillin, amoxicillin and neomycin. Pigment generated by fermentation of the G2 strain has good antioxidant activity, and when the concentration is 10 micrograms / mL, the scavenging activity on DPPH is 25.00%, the scavenging activity on hydroxyl radicals is 80.58%, and the iron ion reducing capacity is 1.57, which are all higher than those of contrast beta-carotenoid. The application of the new Kineococcus strain G2 can lay a foundation for the research of antioxidant drugs such as medical treatment and health care product development.

The invention relates to a method and a kit for detecting a rifampicin drug resistance gene of mycobacterium tuberculosis. The kit comprises polynucleotide primers as shown in SEQ ID NO.1-SEQ ID NO.7. The detection method comprises the following steps: step 1, collecting a sample: collecting a sputum sample of a patient as a test sample; step 2, extracting DNA: extracting DNA of a test sample by using a kit method or a lysis method; 3, preparing a reaction system, and carrying out reaction amplification, namely preparing an amplification reaction system under the guidance of the special primer for the kit by taking the sample DNA in the step 2 as a template, and carrying out specific amplification; step 4, result analysis: in the specific amplification process, due to the difference of amplification target sequences, the basic group contents of amplification products are different; the change of a single basic group can cause the change of the melting temperature of amplified target double chains; the method comprises the following steps: monitoring the change of a fluorescence signal in a temperature rise process in real time, performing data integration and image drawing on a detection result to generate a target product melting curve, and judging the difference of a gene sequence in a target product according to the difference of the melting curve.

The invention discloses a method for constructing a genetic transformation system of cymbidium kanran, which belongs to the technical field of plant genetic engineering, and comprises the following steps of: carrying out monoclonal propagation on rhizomes after germination of cymbidium kanran seeds to obtain vegetative propagules with stable characters, taking the vegetative propagules as transformation receptors, taking GFP (Green Fluorescent Protein) as marker genes, and constructing the genetic transformation system of cymbidium kanran. The method comprises the following steps: adding agrobacterium EHA105 into a YEB liquid culture medium containing 50 mg / L of kanamycin and 25 mg / L of rifampicin as a dip dyeing solution; placing the injured transformation receptor in dip dyeing for transformation, and then carrying out regeneration culture. The invention relates to a method for carrying out genetic transformation on cymbidium kanran by utilizing the innovative receptor and the screening culture medium, and the method can realize efficient and stable genetic transformation without genotype dependence and can solve the problem that the genetic transformation of cymbidium kanran varieties is difficult to carry out. According to the invention, an efficient genetic transformation and regeneration system of cymbidium kanran is established for the first time, and a foundation is laid for verification of related functional genes of cymbidium kanran and further development of biological research of cymbidium transgenic breeding and the like.

The invention discloses a fixing material for a medical device implant and a preparation method of the fixing material. The fixing material comprises a degradable polymer base material with a porous structure and a drug sustained-release coating uniformly loaded on the degradable polymer base material, holes in the degradable polymer are uniformly distributed in a staggered array manner, the holes are circular, the aperture of each hole is 0.5-3.0 mm, and the distance between every two adjacent holes is 0.5-3.0 mm; the drug sustained-release coating contains antibiotics; the antibiotics comprise rifampicin, minocycline hydrochloride, vancomycin, tobramycin, gentamicin and the like. The fixing material disclosed by the invention takes the degradable polymer as a base material, and the drug-loading coating containing antibiotics and anti-inflammatory substances is loaded on the surface, so that slow release of antibiotic drugs can be realized, and the fixing material has excellent antibacterial and anti-inflammatory performance and complete absorbability in a biological environment; and the problems of biocompatibility, infection risk and secondary operation removal of the implant for a long time are solved.

This invention relates to the field of high-throughput targeted sequencing technology, and particularly to a primer set and its applications for detecting important drug resistance and virulence genes in multidrug-resistant pathogens. Specifically, it includes primers for detecting various drug-resistant bacteria, such as third-generation cephalosporin-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and rifampicin-resistant Mycobacterium tuberculosis. This invention offers advantages such as speed, efficiency, strong targeting, and high specificity. It is suitable for analyzing the prevalence and differential distribution of multiple important drug resistance and virulence genes carried in metagenomic samples from various environments or pathogenic materials, and can be used to assess the risk of related environments, further guiding preventative and clinical treatment medications.

This invention belongs to the field of electroluminescence technology, specifically relating to a method for preparing a high-entropy MOF material and its application in the electrochemiluminescence detection of rifampicin. The high-entropy MOF material is a pentagonal high-entropy MOF material (HE-ATA) synthesized from metal nitrates of Fe, Co, Cu, Cr, and Zn and ATA as raw materials. This invention yields a HE-ATA catalyst with simple raw materials, convenient synthesis, and excellent electrochemiluminescence performance. It exhibits chemical stability and a multi-electron reaction potential that accelerates the conversion of dissolved oxygen to reactive oxygen species (ROS), enhancing the electroluminescence intensity. Based on the quenching effect of RIF, a method for detecting RIF using a luminol / HE-ATA system was established. By fitting the change in ECL intensity with RIF concentration, a linear calibration curve with a correlation coefficient of 0.996 and a detection limit of 3.3 × 10⁻⁶ was obtained. ‑6 µM (S / N=3). This material exhibits good sensitivity, stability, and reproducibility in the electrochemiluminescence detection of RIFs, providing a new approach for designing novel electrocatalysts for RIF detection.

This invention relates to a compound antibacterial agent and its application in open plant tissue culture. The active ingredients of the compound antibacterial agent include rifampin, kasugamycin, ticarcillin sodium clavulanic acid, and tetrachloroisophthalonitrile. The compound antibacterial agent can synergistically inhibit Agrobacterium rhizogenes or Rhodotorula glutinis, contaminating bacteria that are easily generated during plant tissue culture.

The invention belongs to the technical field of biomedical nano-materials, and particularly relates to a preparation method and application of responsive nano-particles for targeted removal of fusobacterium nucleatum and a biological membrane of the fusobacterium nucleatum. The ERPNPs is formed by self-assembly of PEG (polyethylene glycol)-b-PCL (polycaprolactone), Pep-PAE (polycaprolactone)-b-PCL (polycaprolactone) and (PBA / PAE)-b-PCL, and the ERPNPs carry rifampicin and gallocatechin gallate together. The nano-system exposes FadA target peptide in an acidic tumor microenvironment, accurately recognizes Fn and synergistically sterilizes and disperses a biological membrane, so that an immunosuppression microenvironment is reversed, and the nano-system has an important application prospect in the development of anti-CRC drugs.

The application belongs to the technical field of biomedicine, and discloses a method for constructing a Channa argus bile stasis model. The application discloses application of rifampicin or a pharmaceutically acceptable salt thereof in construction of a fish liver injury model. The application discloses, for the first time, that the antibiotic rifampicin widely used in aquaculture is used to construct a fish liver injury model. The model is closer to the real scene of the use of a large amount of drugs when bacterial diseases break out in production practice. The injury type of the fish liver injury model is clearly directed to bile stasis, which fills the research blank of the disease model of the fish, and is different from common hepatocyte necrosis or fatty liver models.

The invention discloses a crRNA combination for detecting mycobacterium tuberculosis and a drug-resistant mutation site thereof, a kit and application, and belongs to the technical field of molecular detection. The crRNA combination comprises a crRNA-MTB (Complementary Ribonucleic Acid-Methyl Terminals B) used for detecting the mycobacterium tuberculosis, a crRNA-MTB-rpoB used for detecting the rifampicin drug-resistant mutation site of the mycobacterium tuberculosis, and a crRNA-MTB-katG used for detecting the isoniazide drug-resistant mutation site of the mycobacterium tuberculosis; by designing the specific crRNA combination for detecting the mycobacterium tuberculosis and the drug-resistant mutation site thereof, the sensitivity of detecting the mycobacterium tuberculosis and the drug-resistant mutation site thereof can be remarkably improved, the detection time can be shortened, and synchronous detection of the mycobacterium tuberculosis and the drug-resistant mutation site thereof can be realized, so that the kit has the advantages that the detection sensitivity is greatly improved, and the detection time is shortened. The method has a good application prospect in detection of the mycobacterium tuberculosis and the drug-resistant mutation site of the mycobacterium tuberculosis.

The invention provides a reaction system for detecting mycobacterium tuberculosis and rifampicin drug resistance genes thereof. The reaction system comprises DNA polymerase, dNTPs, a reaction buffer solution and a primer for amplifying a template, the reaction system comprises magnesium ions, disodium hydrogen phosphate and a double-strand displacement probe composition, the reaction system can be combined with the double-strand displacement probe composition through synergy of the magnesium ions and the disodium hydrogen phosphate, and the defects that according to a conventional melting curve method, the number of impure peaks is large, the peak heights of melting curves are inconsistent under the same condition, and the sensitivity of the melting curves is low can be overcome; the method has the advantages of low fluorescence background, high detection sensitivity, good specificity and good stability, the purpose of multiple analysis of rifampicin sensitivity and drug resistance in the same optical channel can be achieved by combining melting curve analysis, and when the reaction system is applied to detection, the obtained melting curve peak shape is more stable than that of a conventional asymmetric PCR system, and the method is suitable for large-scale popularization and application. And the experiment repeatability and consistency are good.

The invention discloses a preparation method of an antibacterial coating material based on synergistic interaction of antibiotics and metal ions. The preparation method comprises the following steps: (1) blending antibiotics, soluble salts of metal ions, an absorbable polymer and a mixed solvent to obtain a coating solution; the antibiotics are selected from rifampicin and minocycline hydrochloride; the metal ions are selected from Zn and / or Cu; the mixed solvent is selected from hexafluoroisopropanol and a methanol / aqueous solution, and the volume ratio of hexafluoroisopropanol in the mixed solvent is not less than 25%; and (2) uniformly spraying the coating solution on the surface of the degradable base material through ultrasonic spraying, and then carrying out drying treatment. The preparation method is easy and convenient to operate, the obtained coating is tightly combined with a degradable base material, and the antibacterial rate can still reach 90% or above after 50 times of washing. According to the prepared antibacterial coating material, the synergistic release mode of rapid sterilization and long-acting bacteriostasis is achieved through raw material screening and process optimization, and the short-term and long-acting antibacterial performance can be remarkably improved.

The invention relates to application of an activating agent in promotion of uranium element discharge. Specifically, the activating agent is prepared from rifampicin, erythromycin, progesterone, aldosterone, bilirubin, cholate vinblastine, doxomicin, adriamycin, paclitaxel, bosentan, ambrisentan, digoxin, verapamil, tonavir, amprenavir, indinavir, hypericum perforatum juice, curcumin, atorvastatin beclomethasone, budesonide, divaricasone carbamazepine and caffeine. And phenytoin. The use dosage of the activating agent is 10 to 60 mg / kg. According to the method, the accumulation amount of uranium in important organs such as bones and kidneys can be remarkably reduced, so that the potential toxic influence on the key organs is reduced.

The invention discloses an application of rifampicin in preparation of a medicine for regulating lipid metabolism. The invention discloses a new medical application of rifampicin by using a mouse model fed by 3T3-L1 fat cells and high fat diet (HFD). Rifampicin can increase the expression of Sirt6 in vivo and in vitro. In addition, rifampicin effectively blocks differentiation of 3T3-L1 preadipocytes and reduces lipid accumulation by inhibiting lipid generation in adipocytes and enhancing lipid decomposition. In the mechanism level, rifampicin significantly inhibits the expression of adipogenesis genes and proteins, and enhances the expression of genes and proteins of lipolysis, energy consumption and white adipose tissue browning related pathways. In conclusion, data of the invention shows that rifampicin is a potential new treatment strategy for regulating lipid metabolism.

The present invention provides an antimicrobial combination comprising three different antimicrobial agents. The first antimicrobial agent is selected from the group consisting of ceftazidime, polymyxin E, polymyxin B, and pharmaceutically acceptable derivatives thereof; the second antimicrobial agent is selected from the group consisting of zidovudine, doxycycline, fosfomycin and pharmaceutically acceptable derivatives thereof; and the third antimicrobial agent is selected from the group consisting of levofloxacin, doxycycline, fosfomycin, meropenem, rifampicin, gentamicin, polymyxin B / E, and pharmaceutically acceptable derivatives thereof; wherein the combination comprises at least one of levofloxacin, doxycycline, rifampicin, fosfomycin, or a pharmaceutically acceptable derivative thereof; with the proviso that the combination is not (1) polymyxin E / B, zidovudine and rifampicin or (2) ceftazidime, zidovudine and fosfomycin. Also provided are antimicrobial combinations comprising three antimicrobial agents, wherein the first antimicrobial agent is ceftazidime or a pharmaceutically acceptable derivative thereof; the second antimicrobial agent is zidovudine or a pharmaceutically acceptable derivative thereof; and the third antimicrobial agent is polymyxin E or a pharmaceutically acceptable derivative thereof.

The invention discloses a mycobacterium tuberculosis rpoB gene mutation detection method based on a CRISPR-Cas12a technology and a kit, and relates to the technical field of molecular biological detection. According to the present invention, through the design and the screening of the specific crRNA, the 531-crRNA4 with the nucleotide sequence represented by SEQ ID NO. 4 is successfully obtained; the sequence is combined with CRISPR-Cas12a and a PCR (Polymerase Chain Reaction) technology, can efficiently detect the rifampicin drug-resistant mutation site S531L, and has the remarkable advantages of high sensitivity, strong specificity, simplicity and convenience in operation and the like. The detection result of a clinical sample is highly consistent with the Sanger sequencing result, the detection time is shortened to be within 2 hours, and the method is suitable for rapid screening of clinical drug resistance. According to the technology, the time for doctors and patients to obtain detection reports is remarkably shortened, and the medical efficiency is effectively improved.

A technique of administering rifampicin over an extended period of time, with reduced side effects. A medicine that is for nasal administration and is used to prevent or treat neurodegenerative diseases, contains a rifampicin selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and a resveratrol selected from resveratrol and derivatives thereof, has reduced side effects, and can be administered over an extended period of time.